Immune Surveillance

  • N. A. Mitchison
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 15B)


The best evidence bearing on immune surveillance comes from studies on the incidence of tumours in human transplant recipients [1]. The most recent U.K./Australasian figures for relative risk (and no. of cases) are as follows: non-Hodgkins lymphoma, 49 (42); skin, 9 (24); melanoma, 9 (2); all others, 1.4 (94). Some and perhaps all of this is indicative of viral oncogenesis. The best animal data concern tumour-specific transplantation antigens (TSTA) in chemically induced [2] and UV-induced [3] cancer.


Epstein Barr Virus Immune Surveillance Transferrin Receptor Major Effector Tumour Immunology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mitchison, N.A., Kinlen, L. (1980) in Immunology ‘80 [4th Int. Congr. Inmunol., Paris, July 1980] (Fougereau, M. and Dausset, J.), Academic Press, London, pp. 641–650.Google Scholar
  2. 2.
    Boon, T. (1983) Adv. Cancer Res. 39, 121–151.CrossRefGoogle Scholar
  3. 3.
    Urban, J.L., Holland, J.M., Kripke, M.L., Schreiber, H. (1982) J. Exp. Med. 157, 642–656.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • N. A. Mitchison
    • 1
  1. 1.Tumour Immunology Unit, Zoology DepartmentUniversity College LondonLondonUK

Personalised recommendations